Cancer · 2011 · 67 citations · 26 references
MedicineOncologyPharmacoeconomicsChemotherapyCost-effectiveness AnalysisCost-utility AnalysisCost-effectiveness ComparisonCost-effectiveness ModelingPancreatic CancerRadiation TherapyComparative Clinical EffectivenessLocal Disease ProgressionLocal Tumor ProgressionOncologic Outcomes AssessmentPancreatic Cancer RadiotherapyQuality-adjusted Life ExpectancyStereotactic Body Radiotherapy ToxicityStereotactic Radiotherapy Toxicity Assessment
BACKGROUND: Radiotherapy may improve the outcome of patients with pancreatic cancer but at an increased cost. In this study, the authors evaluated the cost-effectiveness of modern radiotherapy techniques in the treatment of locally advanced pancreatic cancer. METHODS: A Markov decision-analytic model was constructed to compare the cost-effectiveness of 4 treatment regimens: gemcitabine alone, gemcitabine plus conventional radiotherapy, gemcitabine plus intensity-modulated radiotherapy (IMRT); and gemcitabine with stereotactic body radiotherapy (SBRT). Patients transitioned between the following 5 health states: stable disease, local progression, distant failure, local and distant failure, and death. Health utility tolls were assessed for radiotherapy and chemotherapy treatments and for radiation toxicity. RESULTS: SBRT increased life expectancy by 0.20 quality-adjusted life years (QALY) at an increased cost of $13,700 compared with gemcitabine alone (incremental cost-effectiveness ratio [ICER] = $69,500 per QALY). SBRT was more effective and less costly than conventional radiotherapy and IMRT. An analysis that excluded SBRT demonstrated that conventional radiotherapy had an ICER of $126,800 per QALY compared with gemcitabine alone, and IMRT had an ICER of $1,584,100 per QALY compared with conventional radiotherapy. A probabilistic sensitivity analysis demonstrated that the probability of cost-effectiveness at a willingness to pay of $50,000 per QALY was 78% for gemcitabine alone, 21% for SBRT, 1.4% for conventional radiotherapy, and 0.01% for IMRT. At a willingness to pay of $200,000 per QALY, the probability of cost-effectiveness was 73% for SBRT, 20% for conventional radiotherapy, 7% for gemcitabine alone, and 0.7% for IMRT. CONCLUSIONS: The current results indicated that IMRT in locally advanced pancreatic cancer exceeds what society considers cost-effective. In contrast, combining gemcitabine with SBRT increased clinical effectiveness beyond that of gemcitabine alone at a cost potentially acceptable by today's standards.
26
Howard A. Burris, Malcolm J. Moore, John Sahl Andersen et al. · Journal of Clinical Oncology · 1997 · 5.9K citations
Medicine, Oncology, Pharmacotherapy +16
Recommendations for Reporting Cost-effectiveness Analyses
Joanna E. Siegel · JAMA · 1996 · 1.2K citations
C G Moertel, Stephen Frytak, R. G. Hahn et al. · Cancer · 1981 · 1K citations
Probabilistic Sensitivity Analysis Using Monte Carlo Simulation
Peter M. Doubilet, Colin B. Begg, Milton C. Weinstein et al. · Medical Decision Making · 1985 · 851 citations